Improved antigen yield in pandemic H1N1 (2009) candidate vaccine viruses with chimeric hemagglutinin molecules

Journal of Virology

Volumn 85, Issue 12, 2011, Pages 6086-6090

  Harvey, Ruth ^a   Guilfoyle, Kate A ^a   Roseby, Sarah ^a   Robertson, James S ^a   Engelhardt, Othmar G ^a  

^a NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ;

ANTIGEN PRESENTATION; ARTICLE; CONTROLLED STUDY; EGG; HEMAGGLUTINATION INHIBITION TEST; IMMUNODIFFUSION; INFLUENZA VIRUS A H1N1; NIBRG 118 VIRUS; NIBRG 119 VIRUS; NIBRG 121 VIRUS; NONHUMAN; PR8 VIRUS; PRIORITY JOURNAL; VACCINE PRODUCTION; VIROGENESIS; VIRUS CONCENTRATION; VIRUS STRAIN;

AMINO ACID SEQUENCE; ANIMALS; BASE SEQUENCE; CHICK EMBRYO; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; INFLUENZA A VIRUS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MOLECULAR SEQUENCE DATA; NEURAMINIDASE; PANDEMICS; RECOMBINANT PROTEINS;

EID: 79958156054     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00096-11     Document Type: Article

References (11)

1. Adamo, J. E., T. Liu, F. Schmeisser, and Z. Ye. 2009. Optimizing viral protein yield of influenza strain A/Vietnam/1203/2004 by modification of the neuraminidase gene. J. Virol. 83:4023-4029.
2. Harvey, R., et al. 2010. Improved haemagglutinin antigen content in H5N1 candidate vaccine viruses with chimeric haemagglutinin molecules. Vaccine 28:8008-8014.
3. Harvey, R., J. X. Wheeler, C. L. Wallis, J. S. Robertson, and O. G. Engelhardt. 2008. Quantitation of haemagglutinin in H5N1 influenza viruses reveals low haemagglutinin content of vaccine virus NIBRG-14 (H5N1). Vaccine 26:6550-6554.
4. Hsu, J. C. 1996. Multiple comparisons, theory and methods. Chapman and Hall, London, England.
5. Marsh, G. A., R. Hatami, and P. Palese. 2007. Specific residues of the influenza A virus hemagglutinin viral RNA are important for efficient packing into budding virions. J. Virol. 81:9727-9736.
6. Nicolson, C., D. Major, J. M. Wood, and J. S. Robertson. 2005. Generation of influenza vaccine viruses on Vero cells by reverse genetics: an H5N1 candidate vaccine strain produced under a quality system. Vaccine 23:2943- 2952.
7. Reed, L. J., and H. Muench. 1938. A simple method of estimating fifty percent endpoints. Am. J. Hyg. (Lond.) 27:493-497.
8. Robertson, J. S., et al. 2011. The development of vaccine viruses against pandemic A(H1N1) influenza. Vaccine 29:1836-1843.
9. Subbarao, K., et al. 2003. Evaluation of a genetically modified reassortant H5N1 influenza A virus vaccine candidate generated by plasmid-based reverse genetics. Virology 305:192-200.
10. Wood, J. M., G. C. Schild, R. M. Newman, and V. Seagroatt. 1977. An improved single-radial-immunodiffusion technique for the assay of influenza haemagglutinin antigen: application for the potency determinations of inactivated whole virus and subunit vaccines. J. Biol. Stand. 5:237-247.
11. World Health Organization. 2009. Availability of a candidate reassortant vaccine virus for the novel influenza A (H1N1) vaccine development. NIBRG-121. http://www.who.int/csr/resources/publications/swineflu/2009_05_27_NIBRG121a.pdf.